Juanbi Pill for Rheumatoid Arthritis
Primary Purpose
Juanbi Pill, Rheumatoid Arthritis
Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Juanbi pill
Juanbi pill placebo
Methotrexate
Sponsored by
About this trial
This is an interventional treatment trial for Juanbi Pill focused on measuring Juanbi Pill, Methotrexate, Active, Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria:
- Adults with rheumatoid arthritis (score more then 5 of ACR (American College Of Rheumatology) /EULAR (European League Against Rheumatism), 2009 )
- moderate-to-severe disease activity (Disease Activity Score for 28-joint counts (DAS28) of more than 3.2
- an onset of symptoms within 12 months before enrollment, no prior exposure to more than 10mg oral glucocorticoids or biologic agents
- paid employment or unpaid but measurable work (e.g., caring for a family and home)
Exclusion Criteria:
- combined with other disease such as adjuvant arthritis, lupus arthritis, osteoarthritis and et al.
- abnormal liver and my kidney function
- pregnancy or have a plan of pregnancy,breast feeding women
- severe chronic or acute disease interfering with therapy attendance
- alcohol or substance abuse
Sites / Locations
- Longhua Hospital, Shanghai University of TCMRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Juanbi group
placebo group
Arm Description
participants should administrate both Juanbi pill and Methotrexate
participants should administrate both Juanbi pill placebo and Methotrexate
Outcomes
Primary Outcome Measures
Rate of ACR (American College Of Rheumatology) 50
changes of The Disease Activity Score (DAS) 28
changes of the van der Heijde modified Sharp score
Secondary Outcome Measures
changes of The Disease Activity Score (DAS) 28
changes of The Disease Activity Score (DAS) 28
changes of The Disease Activity Score (DAS) 28
changes of The Disease Activity Score (DAS) 28
Rate of ACR(American College Of Rheumatology)50
Rate of ACR(American College Of Rheumatology)50
Rate of ACR(American College Of Rheumatology)50
Rate of ACR(American College Of Rheumatology)50
Rate of ACR(American College Of Rheumatology)50
change score of Health Assessment Questionnaire - Disability Index
change score of Health Assessment Questionnaire - Disability Index
change score of Health Assessment Questionnaire - Disability Index
change score of Health Assessment Questionnaire - Disability Index
change score of Health Assessment Questionnaire - Disability Index
change score of Health Assessment Questionnaire - Disability Index
change score of Patient Assessment of Arthritis Pain
change score of Patient Assessment of Arthritis Pain
change score of Patient Assessment of Arthritis Pain
change score of Patient Assessment of Arthritis Pain
change score of Patient Assessment of Arthritis Pain
change score of Patient Assessment of Arthritis Pain
change score of Patient Global Assessment of Arthritis
change score of Patient Global Assessment of Arthritis
change score of Patient Global Assessment of Arthritis
change score of Patient Global Assessment of Arthritis
change score of Patient Global Assessment of Arthritis
change score of Patient Global Assessment of Arthritis
change score of 36-item Short-Form Health Survey Questionnaire
change score of 36-item Short-Form Health Survey Questionnaire
change score of 36-item Short-Form Health Survey Questionnaire
change score of 36-item Short-Form Health Survey Questionnaire
change score of 36-item Short-Form Health Survey Questionnaire
change score of 36-item Short-Form Health Survey Questionnaire
change score of AIS Sleep Scale
change score of AIS Sleep Scale
change score of AIS Sleep Scale
change score of AIS Sleep Scale
change score of AIS Sleep Scale
change score of AIS Sleep Scale
rate of ACR20
rate of ACR20
rate of ACR20
rate of ACR20
rate of ACR20
rate of ACR20
rate of ACR70
rate of ACR70
rate of ACR70
rate of ACR70
rate of ACR70
rate of ACR70
Full Information
NCT ID
NCT02885597
First Posted
August 18, 2016
Last Updated
July 13, 2018
Sponsor
Cui xuejun
Collaborators
Shanghai Yueyang Integrated Medicine Hospital, Longhua Hospital, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02885597
Brief Title
Juanbi Pill for Rheumatoid Arthritis
Official Title
Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 2018 (Anticipated)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Cui xuejun
Collaborators
Shanghai Yueyang Integrated Medicine Hospital, Longhua Hospital, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether Juanbi Pill combined with methotrexate are effective in the treatment of active Rheumatoid Arthritis (RA).
Detailed Description
Rheumatoid arthritis patients are suffering from painful and swelling of joints as well as joint destruction and functional disability with the duration of disease activity. Patients and physician try to find a way to alleviate the swell and tenderness of joints to avoid irreversible joints impairment, for evidence indicating that early aggressive treatment results in greater improvement than therapy initiated later in the disease course.
As a complementary and alternative medicine (CAM), herbal medicines have the potential to achieve a clinical remission, or push the disease back to low disease activity. In traditional Chinese medicine (TCM), rheumatoid arthritis is a Bi syndrome and Juanbi decotion (notopterygium root, radix angelicae pubescentis, Gentiana macrophylla, Kadsura Pepper Stem, Mulberry Twig, Angelica sinensis, Ligusticum wallichii, frankincense, Radix Aucklandiae, shaved cinnamon barka and liquorice ) is a medicine specially for Bi syndrome and it has been used in Chinese for hundreds of years. Juanbi pill is the raw extration of Juanbi decotion for the sake of convenience of quality control and storage.
Although the long term usage of Juanbi decotion, there is no high quality evidence about the decotion on rheumatoid arthritis. Using a well-designed clinical trial, the investigators will survey the effectiveness of concurrent use of this decotion in relieving disease activity. Therefore, the present study is to examine effectiveness and safety of Juanbi Pill, a compound traditional Chinese herbal medicine on rheumatoid arthritis in a randomized, double-blind, placebo-controlled trial. Results of this study will provide evidence regarding the value of the Juanbi pill as an intervention to lower the disease activity and protect the affected joints from deformity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Juanbi Pill, Rheumatoid Arthritis
Keywords
Juanbi Pill, Methotrexate, Active, Rheumatoid Arthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Juanbi group
Arm Type
Experimental
Arm Description
participants should administrate both Juanbi pill and Methotrexate
Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
participants should administrate both Juanbi pill placebo and Methotrexate
Intervention Type
Drug
Intervention Name(s)
Juanbi pill
Other Intervention Name(s)
Experimental: Juanbi group
Intervention Description
4g, twice a day, 3month, oral
Intervention Type
Drug
Intervention Name(s)
Juanbi pill placebo
Other Intervention Name(s)
Placebo Comparator: placebo group
Intervention Description
4g, twice a day, 3month, oral
Intervention Type
Drug
Intervention Name(s)
Methotrexate
Other Intervention Name(s)
Experimental: Juanbi group, Placebo Comparator: placebo group
Intervention Description
5mg, once a week, 3 month, oral
Primary Outcome Measure Information:
Title
Rate of ACR (American College Of Rheumatology) 50
Time Frame
at 3 months
Title
changes of The Disease Activity Score (DAS) 28
Time Frame
from baseline to 3 months
Title
changes of the van der Heijde modified Sharp score
Time Frame
from baseline to 12 months
Secondary Outcome Measure Information:
Title
changes of The Disease Activity Score (DAS) 28
Time Frame
from baseline to 2 weeks
Title
changes of The Disease Activity Score (DAS) 28
Time Frame
from baseline to 1 month
Title
changes of The Disease Activity Score (DAS) 28
Time Frame
from baseline to 6 months
Title
changes of The Disease Activity Score (DAS) 28
Time Frame
from baseline to 12 months
Title
Rate of ACR(American College Of Rheumatology)50
Time Frame
at 2 weeks
Title
Rate of ACR(American College Of Rheumatology)50
Time Frame
at 1 month
Title
Rate of ACR(American College Of Rheumatology)50
Time Frame
at 2 months
Title
Rate of ACR(American College Of Rheumatology)50
Time Frame
at 6 months
Title
Rate of ACR(American College Of Rheumatology)50
Time Frame
at 12 months
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 2 weeks
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 1 month
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 2 months
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 3 months
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 6 months
Title
change score of Health Assessment Questionnaire - Disability Index
Time Frame
from baseline to 12 months
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 2 weeks
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 1 month
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 2 months
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 3 months
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 6 months
Title
change score of Patient Assessment of Arthritis Pain
Time Frame
from baseline to 12 months
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 2 weeks
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 1 month
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 2 months
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 3 months
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 6 months
Title
change score of Patient Global Assessment of Arthritis
Time Frame
from baseline to 12 months
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 2 weeks
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 1 month
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 2 months
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 3 months
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 6 months
Title
change score of 36-item Short-Form Health Survey Questionnaire
Time Frame
form baseline to 12 months
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 2 weeks
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 1 month
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 2 months
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 3 months
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 6 months
Title
change score of AIS Sleep Scale
Time Frame
from baseline to 12 months
Title
rate of ACR20
Time Frame
at 2 weeks
Title
rate of ACR20
Time Frame
at 1 month
Title
rate of ACR20
Time Frame
at 2 months
Title
rate of ACR20
Time Frame
at 3 months
Title
rate of ACR20
Time Frame
at 6 months
Title
rate of ACR20
Time Frame
12 months
Title
rate of ACR70
Time Frame
at 2 weeks
Title
rate of ACR70
Time Frame
at 1 month
Title
rate of ACR70
Time Frame
at 2 months
Title
rate of ACR70
Time Frame
at 3 months
Title
rate of ACR70
Time Frame
at 6 months
Title
rate of ACR70
Time Frame
at 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults with rheumatoid arthritis (score more then 5 of ACR (American College Of Rheumatology) /EULAR (European League Against Rheumatism), 2009 )
moderate-to-severe disease activity (Disease Activity Score for 28-joint counts (DAS28) of more than 3.2
an onset of symptoms within 12 months before enrollment, no prior exposure to more than 10mg oral glucocorticoids or biologic agents
paid employment or unpaid but measurable work (e.g., caring for a family and home)
Exclusion Criteria:
combined with other disease such as adjuvant arthritis, lupus arthritis, osteoarthritis and et al.
abnormal liver and my kidney function
pregnancy or have a plan of pregnancy,breast feeding women
severe chronic or acute disease interfering with therapy attendance
alcohol or substance abuse
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yongjun Wang, Doctor
Phone
86-189177763018
Email
yjwang8888@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Qianqian Liang, Doctor
Phone
86-021-64875390
Facility Information:
Facility Name
Longhua Hospital, Shanghai University of TCM
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qianqian Liang, Doctor
Phone
86-021-64875390
Email
liangqianqiantcm@126.com
First Name & Middle Initial & Last Name & Degree
Qiong Wang
Phone
86-13671779096
Email
13671779096@163.com
First Name & Middle Initial & Last Name & Degree
Yongjun Wang, Doctor
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29558967
Citation
Wang Q, Wang YR, Jia QY, Liu L, Xu CQ, Wang XY, Yao M, Cui XJ, Shi Q, Wang YJ, Liang QQ. The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial. Trials. 2018 Mar 20;19(1):188. doi: 10.1186/s13063-018-2555-1.
Results Reference
derived
Learn more about this trial
Juanbi Pill for Rheumatoid Arthritis
We'll reach out to this number within 24 hrs